CHENGDU BRIGHT EYE HOSPITAL CO., LTD. Chengdu Bright Eye Hospital Co., Ltd. Stock
Equities
301239
CNE100005GX3
Healthcare Facilities & Services
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 46.4 CNY | -2.95% |
|
-4.45% | -46.05% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 3.04B 420M | Sales 2025 * | 4.04B 559M | Capitalization | 6.91B 954M |
|---|---|---|---|---|---|
| Net income 2024 * | 160M 22.1M | Net income 2025 * | 356M 49.18M | EV / Sales 2024 * | 2.27 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.71 x |
| P/E ratio 2024 * |
43.4
x | P/E ratio 2025 * |
19.5
x | Employees | 4,918 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 39.21% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.95% | ||
| 1 week | -4.45% | ||
| Current month | -5.75% | ||
| 1 month | -7.79% | ||
| 3 months | -27.66% | ||
| 6 months | -51.63% | ||
| Current year | -46.05% |
1 week
45.05
49.67
1 month
45.0552.26
Current year
45.0585.99
1 year
45.05133.60
3 years
45.05144.88
5 years
45.05144.88
10 years
45.05144.88
| Managers | Title | Age | Since |
|---|---|---|---|
Qiang Sun
CEO | Chief Executive Officer | 43 | 22-10-09 |
Xu Yang Xu
CHM | Chairman | 53 | 06-03-22 |
Guo Ping Yang
DFI | Director of Finance/CFO | 44 | 12-01-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Peng Hui Chen
BRD | Director/Board Member | 52 | 19-09-19 |
De Fang Lei
CHM | Chairman | 56 | 14-03-31 |
Xiao Cong Xiong
BRD | Director/Board Member | 42 | 18-12-27 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-21 | 46.4 | -2.95% | 2,712,367 |
| 24-05-20 | 47.81 | +4.53% | 4,616,437 |
| 24-05-17 | 45.74 | -1.27% | 2,604,803 |
| 24-05-16 | 46.33 | -1.57% | 2,056,329 |
| 24-05-15 | 47.07 | -3.07% | 2,085,211 |
End-of-day quote Shenzhen S.E., May 20, 2024
More quotes
Chengdu Bright Eye Hospital Co Ltd is a China-based company mainly engaged in the operation of chain ophthalmic medical organizations. The Company's main business includes outpatient clinics, clinical services, medical treatment, and medical technology development. The Company's products and services include refractive surgery, medical optometry, ocular plastics, and cataract, glaucoma, strabismus, ocular fundus disease, and ceratonosus diagnosis and treatment. The Company mainly conducts its businesses within the domestic market.
Calendar
2024-05-23
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
46.4
CNY
Average target price
107.7
CNY
Spread / Average Target
+132.07%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -46.05% | 955M | |
| -18.84% | 16.5B | |
| +3.60% | 12.57B | |
| +3.98% | 11.76B | |
| +2.80% | 10.27B | |
| +28.60% | 8.64B | |
| -6.99% | 7.47B | |
| +6.40% | 6.74B | |
| +8.59% | 6.48B | |
| +39.21% | 4.3B |
- Stock Market
- Equities
- 301239 Stock